Transgene . (NASDAQ:TRGNY)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Transgene . Charts. Click Here for more Transgene . Charts.](/p.php?pid=staticchart&s=N%5ETRGNY&p=8&t=15)
Transgene Signs Pre-Clinical AIDS Vaccine Manufacturing Agreement With ANRS and
INSERM
STRASBOURG, France, Nov. 3 /PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY;
Nouveau Marche: FR0005175080) announced today that it has entered into an
agreement with the French AIDS Research Agency (Agence Nationale de Recherches
sur le SIDA /ANRS) and the French Institute for Health and Medical Research
(Institut National de la Sante et de la Recherche Medicale / INSERM) to
construct and manufacture pre-clinical lots of a novel AIDS vaccine.
Transgene will make the constructs consisting of Modified Vaccinia Ankara (MVA)
vectors carrying AIDS virus epitopes from Gag, Nef and Pol genes and will
manufacture the pre-clinical lots. INSERM, which owns the intellectual property
of the Nef protein fragments, will conduct the immunological pre- clinical
testing of the vaccine constructs together with ANRS. Under the terms of this
short-term service agreement, Transgene will receive payment from ANRS.
"We are pleased to collaborate with the ANRS and INSERM on this serious
worldwide public health problem. We believe that this agreement is further
evidence of the broad capability of Transgene's technology both in the
construction and the manufacturing of recombinant vaccines and vectors," said
Jean-Francois Carmier, Chief Executive Officer of Transgene.
About Transgene:
Transgene, based in Strasbourg, France, is a biopharmaceutical company dedicated
to the discovery and development of therapeutic vaccines, immunotherapy
products, and delivery technologies for the treatment of diseases for which
there is no cure or adequate treatment at present, with a focus on the treatment
of cancer. Transgene has five products in clinical development, two of which
are in Phase II clinical trials and three of which have completed Phase I
clinical trials. Transgene's proprietary vector technology platform consists of
adenovirus, poxvirus and non-viral vectors.
This press release contains forward-looking statements. Statements that are not
historical facts are based on Transgene's current expectations, beliefs,
estimates, forecasts and assumptions. Those statements are not guarantees of
future performance and involve certain risks, uncertainties and assumptions
which are difficult to predict. Accordingly, actual outcomes and results may
differ materially from what is expressed in those forward-looking statements.
Important factors that may affect Transgene's future operating results include
the following: Transgene's collaboration agreement with ANRS and INSERM may not
provide Transgene with the anticipated benefits when expected, if at all;
Transgene's product candidates may not demonstrate therapeutic efficacy;
Transgene may be unable to obtain regulatory approval for its product
candidates; Transgene's patent rights may not provide it with any benefit and
the patents of others may prevent it from commercializing its products;
Transgene may be unable to conduct its clinical trials as quickly as it has
predicted; Transgene may not have sufficient resources to complete the research
and commercialization of any of its product candidates; competitors may develop
technologies or products superior to Transgene's technologies or products; and
other important factors described in Transgene's Annual Report on Form 20-F for
the year ended December 31, 2002 filed with the U.S. Securities and Exchange
Commission, including those factors described in the section entitled "Risk
Factors."
DATASOURCE: Transgene
CONTACT: Michel Hubert, V.P., Business Development, Transgene,
+33-3-88-27-91-12; Julie Huang, +1-212-798-9814, or Julio Cantre,
+1-212-798-9779, both of Cohn & Wolfe for Transgene; Marie-Carole de Groc,
+33-1-58-47-95-07, or Odile Rebattet, +33-1-58-47-95-06, both of Euro RSCG
C&O